Nomenclature of monoclonal antibodies (English Wikipedia)

Analysis of information sources in references of the Wikipedia article "Nomenclature of monoclonal antibodies" in English language version.

refsWebsite

Global rank English rank

28web.archive.org

1^st place

18who.int

195^th place

302^nd place

11nih.gov

4^th place

7doi.org

2^nd place

5ama-assn.org

3,257^th place

3,398^th place

3semanticscholar.org

11^th place

8^th place

3drugs.com

399^th place

333^rd place

2nobelprize.org

301^st place

478^th place

1archive.org

6^th place

1cancer.gov

1,684^th place

1,350^th place

1books.google.com

3^rd place

1thieme.de

low place

1handle.net

102^nd place

76^th place

ama-assn.org

"AMA (USAN) Monoclonal antibodies". United States Adopted Names. 2007-08-07. Archived from the original on October 18, 2011. Retrieved 2007-08-15.
"Monoclonal Antibodies". American Medical Association. 4 May 2016. Archived from the original on 23 February 2022. Retrieved 7 August 2020.
"Statement on a Nonproprietary name adopted by the USAN Council: Olaratumab" (PDF). American Medical Association. 2010-03-08. Archived from the original (PDF) on 2012-03-19. Retrieved 2010-06-08.
"Statement on a Nonproprietary name adopted by the USAN Council: Benralizumab" (PDF). American Medical Association. 2010-03-08. Archived from the original (PDF) on 2012-03-19. Retrieved 2010-06-08.

searchusan.ama-assn.org

USAN Council. "Statement On A Nonproprietary Name Adopted By The Usan Council - Rozrolimupab" (PDF). American Medical Association. Archived (PDF) from the original on 2021-10-26. Retrieved 2020-12-06.

archive.org

Janeway, CA Jr.; Travers, P.; Walport, M.; Shlomchik, M. J. (2001). Immunobiology (5th ed.). Garland Publishing. ISBN 978-0-8153-3642-6.

books.google.com

Dübel S, Reichert JM (2014). "76.4.1: Besilesomab". Handbook of Therapeutic Antibodies (2nd ed.). Weinheim, Germany: John Wiley & Sons. p. 2131. ISBN 978-3-527-32937-3.

cancer.gov

"Drug Dictionary: Glembatumumab vedotin". National Cancer Institute. 2011-02-02. Archived from the original on 2015-04-05. Retrieved 2010-12-24.

doi.org

Stern, M.; Herrmann, R. (2005). "Overview of monoclonal antibodies in cancer therapy: present and promise". Critical Reviews in Oncology/Hematology. 54 (1): 11–29. doi:10.1016/j.critrevonc.2004.10.011. PMID 15780905.
Tabrizi, M.; Tseng, C.; Roskos, L. (2006). "Elimination mechanisms of therapeutic monoclonal antibodies". Drug Discovery Today. 11 (1–2): 81–88. doi:10.1016/S1359-6446(05)03638-X. PMID 16478695.
Lordick, F.; Ott, K.; Weitz, J.; Jäger, D. (2008). "The evolving role of catumaxomab in gastric cancer". Expert Opinion on Biological Therapy. 8 (9): 1407–15. doi:10.1517/14712598.8.9.1407. PMID 18694358. S2CID 73237824.
Miyasaka, N. (2009). "Adalimumab for the treatment of rheumatoid arthritis". Expert Review of Clinical Immunology. 5 (1): 19–22. doi:10.1586/1744666X.5.1.19. PMID 20476896. S2CID 34169476.
Veronese, F.; Pasut, G. (2005). "PEGylation, successful approach to drug delivery". Drug Discovery Today. 10 (21): 1451–1458. doi:10.1016/S1359-6446(05)03575-0. PMID 16243265.
Lindenmann, J. (1984). "Origin of the terms 'antibody' and 'antigen'". Scandinavian Journal of Immunology. 19 (4): 281–5. doi:10.1111/j.1365-3083.1984.tb00931.x. PMID 6374880. S2CID 222200504.
Parren, P.; Carter, P.J.; Pluckthun, A. (2017). "Changes to International Nonproprietary Names for antibody therapeutics 2017 and beyond: of mice, men and more". mAbs. 9 (6): 898–906. doi:10.1080/19420862.2017.1341029. PMC 5590622. PMID 28621572.

drugs.com

"International Nonproprietary Names". Drugs.com. Archived from the original on 2022-10-08. Retrieved 2010-12-08.
"Abciximab". Drugs.com. Archived from the original on 2010-04-20. Retrieved 2010-03-13.
"Trastuzumab". Drugs.com. Archived from the original on 2017-07-15. Retrieved 2010-06-08.

handle.net

hdl.handle.net

World Health Organization (2018). "International nonproprietary names for pharmaceutical substances (INN): recommended INN: list 80". WHO Drug Information. 32 (3): 431–2. hdl:10665/330907. License: CC BY-NC-SA 3.0 IGO.

nih.gov

pubmed.ncbi.nlm.nih.gov

Stern, M.; Herrmann, R. (2005). "Overview of monoclonal antibodies in cancer therapy: present and promise". Critical Reviews in Oncology/Hematology. 54 (1): 11–29. doi:10.1016/j.critrevonc.2004.10.011. PMID 15780905.
Tabrizi, M.; Tseng, C.; Roskos, L. (2006). "Elimination mechanisms of therapeutic monoclonal antibodies". Drug Discovery Today. 11 (1–2): 81–88. doi:10.1016/S1359-6446(05)03638-X. PMID 16478695.
Lordick, F.; Ott, K.; Weitz, J.; Jäger, D. (2008). "The evolving role of catumaxomab in gastric cancer". Expert Opinion on Biological Therapy. 8 (9): 1407–15. doi:10.1517/14712598.8.9.1407. PMID 18694358. S2CID 73237824.
Miyasaka, N. (2009). "Adalimumab for the treatment of rheumatoid arthritis". Expert Review of Clinical Immunology. 5 (1): 19–22. doi:10.1586/1744666X.5.1.19. PMID 20476896. S2CID 34169476.
Veronese, F.; Pasut, G. (2005). "PEGylation, successful approach to drug delivery". Drug Discovery Today. 10 (21): 1451–1458. doi:10.1016/S1359-6446(05)03575-0. PMID 16243265.
AGN (1931). "The Late Baron Shibasaburo Kitasato". Canadian Medical Association Journal. 25 (2): 206. PMC 382621. PMID 20318414.
Lindenmann, J. (1984). "Origin of the terms 'antibody' and 'antigen'". Scandinavian Journal of Immunology. 19 (4): 281–5. doi:10.1111/j.1365-3083.1984.tb00931.x. PMID 6374880. S2CID 222200504.
Köhler, G.; Milstein, C. (2005). "Continuous cultures of fused cells secreting antibody of predefined specificity. 1975". Journal of Immunology. 174 (5): 2453–5. PMID 15728446.
Parren, P.; Carter, P.J.; Pluckthun, A. (2017). "Changes to International Nonproprietary Names for antibody therapeutics 2017 and beyond: of mice, men and more". mAbs. 9 (6): 898–906. doi:10.1080/19420862.2017.1341029. PMC 5590622. PMID 28621572.

ncbi.nlm.nih.gov

AGN (1931). "The Late Baron Shibasaburo Kitasato". Canadian Medical Association Journal. 25 (2): 206. PMC 382621. PMID 20318414.
Parren, P.; Carter, P.J.; Pluckthun, A. (2017). "Changes to International Nonproprietary Names for antibody therapeutics 2017 and beyond: of mice, men and more". mAbs. 9 (6): 898–906. doi:10.1080/19420862.2017.1341029. PMC 5590622. PMID 28621572.

nobelprize.org

"The Nobel Prize in Physiology or Medicine 1901". Nobel Foundation. Archived from the original on 2007-07-16. Retrieved 2011-02-19.
"The Nobel Prize in Physiology or Medicine 1984". Nobel Foundation. Archived from the original on 2018-12-26. Retrieved 2011-02-14.

semanticscholar.org

api.semanticscholar.org

Lordick, F.; Ott, K.; Weitz, J.; Jäger, D. (2008). "The evolving role of catumaxomab in gastric cancer". Expert Opinion on Biological Therapy. 8 (9): 1407–15. doi:10.1517/14712598.8.9.1407. PMID 18694358. S2CID 73237824.
Miyasaka, N. (2009). "Adalimumab for the treatment of rheumatoid arthritis". Expert Review of Clinical Immunology. 5 (1): 19–22. doi:10.1586/1744666X.5.1.19. PMID 20476896. S2CID 34169476.
Lindenmann, J. (1984). "Origin of the terms 'antibody' and 'antigen'". Scandinavian Journal of Immunology. 19 (4): 281–5. doi:10.1111/j.1365-3083.1984.tb00931.x. PMID 6374880. S2CID 222200504.

thieme.de

roempp.thieme.de

Entry on Stamulumab. at: Römpp Online. Georg Thieme Verlag, retrieved 2021-11-17.

web.archive.org

World Health Organization (November 2021), New INN monoclonal antibody (mAb) nomenclature scheme: Geneva, November 2021 (PDF), archived (PDF) from the original on 2021-11-09, retrieved 2021-11-09.
World Health Organization (2021-10-31), New INN monoclonal antibody (mAb) nomenclature scheme: International Nonproprietary Names scheme for monoclonal antibody (mAb), archived from the original on 2021-11-09, retrieved 2021-11-09.
"General policies for monoclonal antibodies" (PDF). World Health Organization. 2009-12-18. Archived (PDF) from the original on 2016-03-03. Retrieved 2010-06-08.
"Guidelines on the Use of International Nonproprietary Names (INNs) for Pharmaceutical Substances" (PDF). 1997. pp. 27–28. Archived (PDF) from the original on 2012-10-18. Retrieved 2007-08-15.
"AMA (USAN) Monoclonal antibodies". United States Adopted Names. 2007-08-07. Archived from the original on October 18, 2011. Retrieved 2007-08-15.
World Health Organization (2017-05-26), Revised monoclonal antibody (mAb) nomenclature scheme: Geneva, 26 May 2017 (PDF), archived (PDF) from the original on 2021-06-05, retrieved 2021-11-09.
"International Nonproprietary Names" (PDF). WHO Drug Information. 23 (3). World Health Organization: 195–199. 2009. Archived (PDF) from the original on 2021-07-11. Retrieved 2010-12-08.
"International Nonproprietary Names for Pharmaceutical Substances (INN)" (PDF). WHO Drug Information. 18 (1). World Health Organization: 61. 2004. Archived from the original (PDF) on September 19, 2007. Retrieved 2010-06-08.
"International Nonproprietary Names for Pharmaceutical Substances (INN)" (PDF). WHO Drug Information. 15 (2). World Health Organization: 121. 2001. Archived (PDF) from the original on 2012-02-11. Retrieved 2010-06-08.
"International Nonproprietary Names for Pharmaceutical Substances (INN)" (PDF). WHO Drug Information. 18 (2). World Health Organization: 167. 2004. Archived from the original (PDF) on November 4, 2005. Retrieved 2011-02-13.
"International Nonproprietary Names for Pharmaceutical Substances (INN)" (PDF). WHO Drug Information. 22 (3). World Health Organization: 221. 2008. Archived (PDF) from the original on 2021-07-14. Retrieved 2010-06-08.
"Drug Dictionary: Glembatumumab vedotin". National Cancer Institute. 2011-02-02. Archived from the original on 2015-04-05. Retrieved 2010-12-24.
"ATC/DDD Classification (final)". WHO Drug Information. 15 (2). World Health Organization. 2001. Archived from the original on July 22, 2011. Retrieved 2011-02-13.
"The use of stems in the selection of International Nonproprietary Names (INN) for pharmaceutical substances" (PDF). World Health Organization. 2009. pp. 107–109, 168–169. Archived (PDF) from the original on 2018-09-20. Retrieved 2010-02-22.
"Monoclonal Antibodies". American Medical Association. 4 May 2016. Archived from the original on 23 February 2022. Retrieved 7 August 2020.
"Revised monoclonal antibody (mAb) nomenclature scheme" (PDF). Geneva: World Health Organization (WHO). 26 May 2017. Archived (PDF) from the original on 5 June 2021. Retrieved 6 August 2020.
International Nonproprietary Names (INN) for biological and biotechnological substances (a review) (PDF) (Report). 2019. WHO/EMP/RHT/TSN/2019.1. Archived (PDF) from the original on 2022-01-19. Retrieved 2020-08-08.
"The Nobel Prize in Physiology or Medicine 1901". Nobel Foundation. Archived from the original on 2007-07-16. Retrieved 2011-02-19.
"The Nobel Prize in Physiology or Medicine 1984". Nobel Foundation. Archived from the original on 2018-12-26. Retrieved 2011-02-14.
"International Nonproprietary Names". Drugs.com. Archived from the original on 2022-10-08. Retrieved 2010-12-08.
"Statement on a Nonproprietary name adopted by the USAN Council: Olaratumab" (PDF). American Medical Association. 2010-03-08. Archived from the original (PDF) on 2012-03-19. Retrieved 2010-06-08.
"64th Consultation on International Nonproprietary Names for Pharmaceutical Substances, Geneva, 4-7 April 2017 Executive Summary" (PDF). World Health Organization. 2017-07-31. Archived (PDF) from the original on 2022-01-19. Retrieved 2017-08-22.
"Abciximab". Drugs.com. Archived from the original on 2010-04-20. Retrieved 2010-03-13.
"Trastuzumab". Drugs.com. Archived from the original on 2017-07-15. Retrieved 2010-06-08.
"International Nonproprietary Names for Pharmaceutical Substances (INN)" (PDF). WHO Drug Information. 16 (3). World Health Organization: 264. 2002. Archived from the original (PDF) on 2010-01-21. Retrieved 2010-06-08.
"International Nonproprietary Names (INN) for Pharmaceutical Substances: Names for radicals & groups comprehensive list" (PDF). World Health Organization. 2002. p. 22. Archived from the original (PDF) on July 3, 2011. Retrieved 2010-12-24.
USAN Council. "Statement On A Nonproprietary Name Adopted By The Usan Council - Rozrolimupab" (PDF). American Medical Association. Archived (PDF) from the original on 2021-10-26. Retrieved 2020-12-06.
"Statement on a Nonproprietary name adopted by the USAN Council: Benralizumab" (PDF). American Medical Association. 2010-03-08. Archived from the original (PDF) on 2012-03-19. Retrieved 2010-06-08.

who.int

World Health Organization (2021-10-31), New INN monoclonal antibody (mAb) nomenclature scheme: International Nonproprietary Names scheme for monoclonal antibody (mAb), archived from the original on 2021-11-09, retrieved 2021-11-09.
"General policies for monoclonal antibodies" (PDF). World Health Organization. 2009-12-18. Archived (PDF) from the original on 2016-03-03. Retrieved 2010-06-08.
"New INN monoclonal antibody (mAb) nomenclature scheme (May 2022)". WHO. 2 May 2022. Retrieved 9 May 2022.
World Health Organization (2017-05-26), Revised monoclonal antibody (mAb) nomenclature scheme: Geneva, 26 May 2017 (PDF), archived (PDF) from the original on 2021-06-05, retrieved 2021-11-09.
"International Nonproprietary Names" (PDF). WHO Drug Information. 23 (3). World Health Organization: 195–199. 2009. Archived (PDF) from the original on 2021-07-11. Retrieved 2010-12-08.
"International Nonproprietary Names for Pharmaceutical Substances (INN)" (PDF). WHO Drug Information. 22 (3). World Health Organization: 221. 2008. Archived (PDF) from the original on 2021-07-14. Retrieved 2010-06-08.
"The use of stems in the selection of International Nonproprietary Names (INN) for pharmaceutical substances" (PDF). World Health Organization. 2009. pp. 107–109, 168–169. Archived (PDF) from the original on 2018-09-20. Retrieved 2010-02-22.
"Revised monoclonal antibody (mAb) nomenclature scheme" (PDF). Geneva: World Health Organization (WHO). 26 May 2017. Archived (PDF) from the original on 5 June 2021. Retrieved 6 August 2020.
International Nonproprietary Names (INN) for biological and biotechnological substances (a review) (PDF) (Report). 2019. WHO/EMP/RHT/TSN/2019.1. Archived (PDF) from the original on 2022-01-19. Retrieved 2020-08-08.
"64th Consultation on International Nonproprietary Names for Pharmaceutical Substances, Geneva, 4-7 April 2017 Executive Summary" (PDF). World Health Organization. 2017-07-31. Archived (PDF) from the original on 2022-01-19. Retrieved 2017-08-22.

whqlibdoc.who.int

"Guidelines on the Use of International Nonproprietary Names (INNs) for Pharmaceutical Substances" (PDF). 1997. pp. 27–28. Archived (PDF) from the original on 2012-10-18. Retrieved 2007-08-15.
"International Nonproprietary Names for Pharmaceutical Substances (INN)" (PDF). WHO Drug Information. 18 (1). World Health Organization: 61. 2004. Archived from the original (PDF) on September 19, 2007. Retrieved 2010-06-08.
"International Nonproprietary Names for Pharmaceutical Substances (INN)" (PDF). WHO Drug Information. 15 (2). World Health Organization: 121. 2001. Archived (PDF) from the original on 2012-02-11. Retrieved 2010-06-08.
"International Nonproprietary Names for Pharmaceutical Substances (INN)" (PDF). WHO Drug Information. 18 (2). World Health Organization: 167. 2004. Archived from the original (PDF) on November 4, 2005. Retrieved 2011-02-13.
"International Nonproprietary Names for Pharmaceutical Substances (INN)" (PDF). WHO Drug Information. 16 (3). World Health Organization: 264. 2002. Archived from the original (PDF) on 2010-01-21. Retrieved 2010-06-08.

apps.who.int

"ATC/DDD Classification (final)". WHO Drug Information. 15 (2). World Health Organization. 2001. Archived from the original on July 22, 2011. Retrieved 2011-02-13.
"International Nonproprietary Names (INN) for Pharmaceutical Substances: Names for radicals & groups comprehensive list" (PDF). World Health Organization. 2002. p. 22. Archived from the original (PDF) on July 3, 2011. Retrieved 2010-12-24.

cdn.who.int

World Health Organization (November 2021), New INN monoclonal antibody (mAb) nomenclature scheme: Geneva, November 2021 (PDF), archived (PDF) from the original on 2021-11-09, retrieved 2021-11-09.